1-hydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione

Description

1-hydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione is a complex organic compound with a rather long and complicated name. It's more commonly known as **Mitoxantrone**.

**Mitoxantrone** is a synthetic, water-soluble anthracenedione derivative. It is a type of **antineoplastic** drug, meaning it's used to treat cancer.

**Why is it important for research?**

Mitoxantrone is a clinically important drug with several unique features that make it a target for research:

* **Mechanism of action:** Mitoxantrone works by interfering with the DNA replication process of cancer cells, effectively stopping their growth. This makes it an interesting compound for understanding how to target DNA replication for cancer therapy.
* **Applications in various cancers:** Mitoxantrone is used to treat several types of cancer, including breast cancer, leukemia, lymphoma, and prostate cancer. Researchers are investigating its potential effectiveness against other cancers and exploring new ways to administer it.
* **Side effects and drug resistance:** Like many other chemotherapy drugs, mitoxantrone has side effects. Researchers are working to understand the mechanism behind these side effects and develop strategies to minimize them. They are also investigating ways to overcome drug resistance that may develop in cancer cells over time.
* **Potential for drug development:** Mitoxantrone's unique structure and mechanism of action have inspired the development of new anthracenedione-based drugs with improved effectiveness and fewer side effects.

**In summary,** Mitoxantrone is a crucial molecule in cancer research due to its clinical importance, unique mechanism of action, and potential for development of new anti-cancer therapies. Ongoing research aims to improve its effectiveness, reduce its side effects, and explore its applications in new treatment regimens.

1-hydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]